Physician profile
Louis A Tartaglia
NPI 1811978455
$313,681.41
in general payments reported to CMS, 2019-2025
34 companies · $85K in 2025
The $85K reported for 2025 was more than what 97% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $16K · 2021: $52K · 2022: $37K · 2023: $53K · 2024: $38K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $86K · Consulting Fee: $37K · Travel and Lodging: $22K · Honoraria: $18K · Food and Beverage: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,275 · Education: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $86,410.00 |
| Consulting Fee | $36,596.00 |
| Travel and Lodging | $22,317.16 |
| Honoraria | $18,100.00 |
| Food and Beverage | $10,817.61 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,275.00 |
| Education | $428.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $202,084.63 | 2019-2025 | Xywav |
| Axsome Therapeutics, INC. | $42,879.35 | 2022-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $33,976.95 | 2023-2025 | Lumryz |
| Harmony Biosciences LLC | $31,186.38 | 2020-2025 | Wakix |
| United Therapeutics Corporation | $513.18 | 2019-2025 | Tyvaso, Tyvaso, Remodulin |
| Idorsia Pharmaceuticals US INC | $290.67 | 2022-2024 | Quviviq |
| Inspire Medical Systems, INC. | $284.49 | 2022-2025 | Inspire |
| Genzyme Corporation | $273.66 | 2021-2025 | |
| Baxter Healthcare | $265.11 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Eisai INC. | $251.82 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.78 | 2021-2025 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $171.24 | 2022-2024 | Glassia |
| Merck Sharp & Dohme LLC | $157.67 | 2019-2025 | Winrevair |
| Regeneron Healthcare Solutions, INC. | $122.55 | 2022-2024 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $119.40 | 2022-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $114.98 | 2023 | Korlym |
| Insmed, INC. | $107.14 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $83.46 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $83.13 | 2024-2025 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $72.94 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Mylan Specialty L.P. | $71.80 | 2021-2024 | Yupelri |
| Grifols USA, LLC | $57.25 | 2022-2025 | Prolastin-C Liquid |
| Inogen, INC. | $53.12 | 2023-2025 | Inogen |
| Viatris Specialty LLC | $50.17 | 2025 | Yupelri |
| Philips North America LLC | $48.37 | 2019-2023 | |
| Azurity Pharmaceuticals, INC. | $32.57 | 2023-2024 | Horizant, Horizant |
| Astrazeneca Pharmaceuticals Lp | $28.88 | 2023-2025 | Fasenra, Airsupra |
| Covis Pharma Gmbh | $24.36 | 2022 | |
| La Jolla Pharmaceutical Company | $19.44 | 2022 | |
| Fisher & Paykel Healthcare INC | $19.00 | 2024 | Fisher & Paykel Healthcare |
| Mallinckrodt Enterprises LLC | $16.05 | 2019 | |
| Advanced Respiratory, INC | $15.60 | 2020 | |
| Amgen INC. | $14.47 | 2024 | Tezspire |
| Janssen Pharmaceuticals, INC | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Tartaglia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.